Biorizon Biotech Doubles Sales and Plans to Reach New Markets by 2023

Biorizon Biotech, an Almeria-based biotech company, which presented its new line of products for regenerative agriculture at Fruit Logistica 2023 this year, experienced a spectacular increase in sales last year. This new sales record has been the result of its rapid growth in EMEA and the Americas, as well as the success of the new products launched in 2022.

Biorizon Biotech is a global player in the cultivation and commercialization of microalgae-based bio solutions for agriculture. Its research and product development is based not only on microalgae but also on various microorganisms and plant extracts aimed at creating biostimulants and biopesticides to enhance Regenerative Agriculture.

The markets that have grown the most in the last year have been EMEA, where Biorizon Biotech has opened a subsidiary in Italy, joining the existing ones; LATAM with a particularly positive sales performance, and ASIA which is emerging strongly.

If you want to read more details about Biorizon Biotech and to find the most important business news of the day, download for free our companion app. the Born2Invets mobile app keeps its readers up to date with the most important news from around the world.

New product lines are already underway

The launch of new product lines aimed at Regenerative Agriculture and new formulations where microalgae, bacteria, and plant extracts are used under the proprietary Trietech technology also responsible for this high growth, has been the focus of attention at Fruit Logistica 2023.

“Biorizon Biotech’s commitment to Regenerative Agriculture, biostimulants, and new-generation biopesticides is total. We believe that the world market will undergo a revolution with the development of these new products and we want to be protagonists of it” said its CEO David Iglesias.

In 2023, Biorizon Biotech will not stop growing

The growth foreseen for 2023 will mark a new milestone for the Biorizon Group and for this new markets are being opened in the continents with current presence, as well as in Asia and Oceania. Biorizon Biotech aims to operate in more than 40 markets this year.

The new facilities, the largest in Europe, in which selected strains of microalgae are cultivated, and the expansion of bacterial production facilities will enable the company to meet the growth expected during 2023.

The market for biostimulants and biopesticides will see significant growth in the next 10 years, and strategies such as the European Union’s “Farm to Fork” strategy and the new legislation approved in important countries such as the USA and Brazil will strengthen this growth.

Biorizon Biotech is adhered to the Global Climate Pact and promotes numerous actions for sustainable cultivation and the reduction of the use of chemical products in agriculture.

__

(Featured image by  Couleur via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in MERCADOS, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.